• Oblokulov A.R
  • Elmurodova A.A.
  • Mukhtorova Sh.A
  • Nurova O.K.
Keywords: coronavirus infection, COVID-19, favipiravir, remdesivir, SARS-CoV-2, viral pneumonia


The article presents the data of a post-registration observational study to evaluate the results of the use of remdesivir and favipiravir in an infectious hospital.

The aim is to evaluate the efficacy and safety of the use of the drugs remdesivir and favipiravir in hospitalized patients with pneumonia caused by the SARS-CoV-2 virus.

Materials and methods. The study included 150 patients aged 18 to 98 years hospitalized with COVID-19, confirmed by PCR and complicated by pneumonia. 60 patients received remdesivir, and 90 - favipiravir of these.

Results. The average period before reaching a satisfactory condition and discharge from the hospital was significantly less in the group receiving remdesivir than when using favipiravir. There is less need to replace therapy, there have been no cases of its cancellation due to poor tolerability when using remdesivir.

Conclusion. Remdesivir is a more effective and safer drug for the treatment of COVID-19 in patients with pneumonia


1. CDC, COVID Data Tracker, Cent. Dis. Control Prev. (2020), (available at https://covid.cdc.gov/covid-data-tracker).
2. W.H.O. Coronavirus, (COVID-19) Dashboard, (available at https://covid19.who.int).
3. Wang D, Hu B, Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323:1061-1069.
4. Arshad U, Pertinez H, Box H, Tatham L, Rajoki RKR, Curley P, et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775-790. doi: 10.1002/cpt.1909.
5. Baden LR, Rubin EJ. Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020;382(19):1851-1852. doi: 10.1056/NEJMe2005477.
6. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020;40(5):416-437. doi: 10.1002/phar.2398.
7. Oblokulov A.R., Niyozov G.E. (2020). Clinical and epidemiological characteristics of patients with COVID - 19 International Journal of Pharmaceutical Research, 12 (4), pp. 3749 - 3752.
8. Raximovich, O.A., Sadilloyevna, J.A., Abdulloyevna, M.S. and Farxodovich, R.F. 2022. Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. 3, 2 (Apr. 2022), 289-294. doi.org/10.17605/OSF.IO/9CFP6.
9. Oblokulov, A. R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for Cell Biology, 5220-5224.
10. Elmurodova A. A. (2022) “Specific Features of the Hemostatic System in Covid-19”. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES 3, 82-85.
11. Hassaniazad, M, Farshidi, H, Gharibzadeh, A, et al. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.J Med Virol. 2022;-8. doi:10.1002/jmv.27724.
12. Cheng, Q, Zhao, G, Chen, J, Jia, Q, Fang, Z. Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: a network meta-analysis of randomized controlled trials. J Med Virol. 2022; 94: 1617-1626. doi:10.1002/jmv.27512
13. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
14. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541-104541. doi.org/10.1016/j.antiviral. 2019.104541.
15. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324:1048-1057. doi:10.1001/jama.2020.16349.
16. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399-20. doi: 10.1128/AAC.00399-20.
17. Maarten J. Postma, Jagpreet Chhatwal COVID-19 Health Economics: Looking Back and Scoping the Future Value in Health, Volume 25, Issue 5, May 2022, Pages 695-696
18. Wang Y, Zhang D, Du G, Du R, Zhao J, Yang J, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi.org/10.1016/S0140-6736(20)31022-9.
19. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, Volume 25: Issue 3. 5220–5224.
How to Cite
Oblokulov A.R, Elmurodova A.A., Mukhtorova Sh.A, & Nurova O.K. (2022). EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN PATIENTS HOSPITALIZED WITH COVID-19. Central Asian Journal of Medical and Natural Science, 3(3), 444-448. https://doi.org/10.17605/cajmns.v3i3.807